Balance Sheet
Accounts PayablesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesLiabilities and Shareholders EquityNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsPayablesPrepaid AssetsRetained EarningsShareholder's EquityTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Viking Therapeutics (VKTX) Common Equity: 2014-2025

Historic Common Equity for Viking Therapeutics (VKTX) over the last 11 years, with Sep 2025 value amounting to $713.0 million.

  • Viking Therapeutics' Common Equity fell 21.77% to $713.0 million in Q3 2025 from the same period last year, while for Sep 2025 it was $713.0 million, marking a year-over-year decrease of 21.77%. This contributed to the annual value of $880.3 million for FY2024, which is 152.65% up from last year.
  • Latest data reveals that Viking Therapeutics reported Common Equity of $713.0 million as of Q3 2025, which was down 10.36% from $795.5 million recorded in Q2 2025.
  • Viking Therapeutics' Common Equity's 5-year high stood at $933.9 million during Q1 2024, with a 5-year trough of $134.1 million in Q1 2023.
  • Moreover, its 3-year median value for Common Equity was $795.5 million (2025), whereas its average is $658.1 million.
  • Per our database at Business Quant, Viking Therapeutics' Common Equity declined by 29.01% in 2022 and then spiked by 596.60% in 2024.
  • Over the past 5 years, Viking Therapeutics' Common Equity (Quarterly) stood at $201.9 million in 2021, then dropped by 28.02% to $145.3 million in 2022, then skyrocketed by 139.76% to $348.4 million in 2023, then skyrocketed by 152.65% to $880.3 million in 2024, then dropped by 21.77% to $713.0 million in 2025.
  • Its last three reported values are $713.0 million in Q3 2025, $795.5 million for Q2 2025, and $846.9 million during Q1 2025.